Despite a major trial setback earlier this year and increasing questions over its efficacy, medtech Grail has beaten the odds and seen a positive recommendation for its multi-cancer blood test Galleri from FDA advisors.
- Home |
- Grail survives adcomm vote as it awaits FDA decision for cancer blood test
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
- September 24, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
